GSK3β Phosphorylation of the KLF6 Tumor Suppressor Promotes Its Transactivation of P21

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2012 Oct 23

PMID 23085750

Citations 29

Authors

U E Lang

P Kocabayoglu

G Z Cheng

Z Ghiassi-Nejad

U Munoz

D Vetter

D A Eckstein

R A Hannivoort

M J Walsh

S L Friedman

Affiliations

Soon will be listed here.

Abstract

KLF6, a ubiquitously expressed Krüppel-like transcription factor, is frequently inactivated in human cancer and has significant roles in cellular proliferation, apoptosis, differentiation and development. A key mechanism of KLF6-mediated growth suppression is through p53-independent transactivation of p21. Several cancer-derived KLF6 mutants lead to the loss of p21-mediated growth suppression through an unknown mechanism. Because several colorectal cancer and hepatocellular carcinoma-derived KLF6 mutations affect a glycogen synthase kinase 3β (GSK3β) phosphorylation consensus site, we investigated the role of GSK3β in the regulation of KLF6 function. Based on transient transfection, GSK3β augments the transactivation of a p21 promoter luciferase by KLF6. Reciprocal co-immunoprecipitation of hemagglutinin (HA)-GSK3β and Flag-KLF6 validated the interaction between these two proteins. KLF6 phosphorylation is augmented in the presence of GSK3β based on in vitro and in vivo (32)P incorporation assays. Site-directed mutagenesis of the candidate phosphorylation sites to alanines ('KLF6-4A' phosphomutant) eliminated a higher molecular weight phosphorylated isoform of KLF6 based on western blot. GSK3β augmented the transactivation by wild-type KLF6, but not KLF6-4A, towards the p21 promoter, and increased p21 protein. Functionally, GSK3β enhanced KLF6-mediated growth suppression, which was abrogated by the KLF6-4A phosphomutant. These data establish that GSK3β directly phosphorylates KLF6, which augments its induction of p21 and resultant growth suppression. This interaction may account for the growth-promoting effects of cancer-derived KLF6 mutants that lack tumor suppressor activity.

Citing Articles

Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/β-catenin pathways.

Wang X, Luo L, Xu J, Lu Q, Xia H, Huang Y Genes Dis. 2023; 11(2):1050-1065.

PMID: 37692489 PMC: 10491917. DOI: 10.1016/j.gendis.2023.03.031.

Prediction of Potential Biomarkers in Early-Stage Nasopharyngeal Carcinoma Based on Platelet RNA Sequencing.

Xu Y, Chen L, Chen Y, Ye W, Huang X, Ke M Mol Biotechnol. 2022; 65(7):1096-1108.

PMID: 36447000 PMC: 10271896. DOI: 10.1007/s12033-022-00611-z.

Differential microRNA profiles of intramuscular and secreted extracellular vesicles in human tissue-engineered muscle.

Vann C, Zhang X, Khodabukus A, Orenduff M, Chen Y, Corcoran D Front Physiol. 2022; 13:937899.

PMID: 36091396 PMC: 9452896. DOI: 10.3389/fphys.2022.937899.

KLF6 facilitates differentiation of odontoblasts through modulating the expression of P21 in vitro.

Chen Z, Wu W, Zheng C, Lan Y, Xie H, Xie Z Int J Oral Sci. 2022; 14(1):20.

PMID: 35422483 PMC: 9010434. DOI: 10.1038/s41368-022-00172-6.

lncRNA OR3A4 Promotes the Proliferation and Metastasis of Ovarian Cancer Through KLF6 Pathway.

Guo F, Du J, Liu L, Gou Y, Zhang M, Sun W Front Pharmacol. 2021; 12:727876.

PMID: 34776953 PMC: 8578722. DOI: 10.3389/fphar.2021.727876.

References

Nejak-Bowen K, Monga S . Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol. 2010; 21(1):44-58. PMC: 3050081. DOI: 10.1016/j.semcancer.2010.12.010. View

Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K . In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene. 2007; 26(30):4428-34. DOI: 10.1038/sj.onc.1210223. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Aberle H, Bauer A, Stappert J, Kispert A, Kemler R . beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997; 16(13):3797-804. PMC: 1170003. DOI: 10.1093/emboj/16.13.3797. View

Li D, Yea S, Li S, Chen Z, Narla G, Banck M . Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem. 2005; 280(29):26941-52. DOI: 10.1074/jbc.M500463200. View

Zeng C, Wang R, Li D, Lin X, Wei Q, Yuan Y . A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology. 2010; 52(5):1702-12. DOI: 10.1002/hep.23875. View

Lee U, Ghiassi-Nejad Z, Paris A, Yea S, Narla G, Walsh M . Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett. 2010; 584(5):1006-10. PMC: 2827621. DOI: 10.1016/j.febslet.2010.01.049. View

Banck M, Beaven S, Narla G, Walsh M, Friedman S, Beutler A . KLF6 degradation after apoptotic DNA damage. FEBS Lett. 2006; 580(30):6981-6. DOI: 10.1016/j.febslet.2006.10.077. View

Huang H, Lee T, Tzeng S, Horng J . KinasePhos: a web tool for identifying protein kinase-specific phosphorylation sites. Nucleic Acids Res. 2005; 33(Web Server issue):W226-9. PMC: 1160232. DOI: 10.1093/nar/gki471. View

10.

Yang J, Roberts L . Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. PMC: 3926946. DOI: 10.1038/nrgastro.2010.100. View

11.

Li D, Yea S, Dolios G, Martignetti J, Narla G, Wang R . Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Res. 2005; 65(20):9216-25. DOI: 10.1158/0008-5472.CAN-05-1040. View

12.

Reeves H, Narla G, Ogunbiyi O, Haq A, Katz A, Benzeno S . Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 2004; 126(4):1090-103. DOI: 10.1053/j.gastro.2004.01.005. View

13.

Slavin D, Koritschoner N, Prieto C, Lopez-Diaz F, Chatton B, Bocco J . A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function. Oncogene. 2004; 23(50):8196-205. DOI: 10.1038/sj.onc.1208020. View

14.

Benzeno S, Narla G, Allina J, Cheng G, Reeves H, Banck M . Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 2004; 64(11):3885-91. DOI: 10.1158/0008-5472.CAN-03-2818. View

15.

Whittaker S, Marais R, Zhu A . The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29(36):4989-5005. DOI: 10.1038/onc.2010.236. View

16.

DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose S, Buller R . E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene. 2006; 25(44):6026-31. DOI: 10.1038/sj.onc.1209611. View

17.

Narla G, Heath K, Reeves H, Li D, Giono L, Kimmelman A . KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 2001; 294(5551):2563-6. DOI: 10.1126/science.1066326. View

18.

Rodriguez E, Aburjania N, Priedigkeit N, DiFeo A, Martignetti J . Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One. 2010; 5(9). PMC: 2936564. DOI: 10.1371/journal.pone.0012639. View

19.

Liu N, Li H, Li S, Shen M, Xiao N, Chen Y . The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem. 2010; 285(24):18858-67. PMC: 2881808. DOI: 10.1074/jbc.M109.099440. View

20.

Liu C, Li Y, Semenov M, Han C, Baeg G, Tan Y . Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002; 108(6):837-47. DOI: 10.1016/s0092-8674(02)00685-2. View